Evaluation of the Safety and Performance of the MILTA GYNECO Vaginal Probe in Postmenopausal Women With Vaginal Atrophy

Exclusion Criteria

• •Patient not available for the 6-week follow-up.
• •Patient presenting with pelvic pain of physical and / or psychological origin.
• •* Patients undergoing initial treatment for cancer and/or who have completed their treatments within the last year
• •* Patient with immunosuppression.
• •* Allergy to the material of the probe protection used (latex for example).
• •Pregnancy.
• •Implantable device active in the heart such as a defibrillator or a pacemaker, neuromodulation stimulator, electrodes implanted for the treatment of Parkinson's disease.
• •Epilepsy, photophobia, recent intake of photosensitizing drugs or cosmetics (in the last 6 months), history of porphyria.
• •Patient participating in category 1 interventional study.
• •Patient in an exclusion period determined by another study.
• •Patient under legal protection, under guardianship or under curatorship.
• •Patient for whom it is impossible to give informed information.